Infinity Pharmaceuticals Inc.  

(Public, NASDAQ:INFI)   Watch this stock  
Find more results for INFI
16.94
+0.81 (5.02%)
Dec 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.19 - 16.94
52 week 8.40 - 18.25
Open 16.21
Vol / Avg. 598,704.00/771,922.00
Mkt cap 793.64M
P/E     -
Div/yield     -
EPS -0.27
Shares 48.77M
Beta 1.14
Inst. own 95%
Feb 23, 2015
Q4 2014 Infinity Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 1, 2014
Infinity Pharmaceuticals Inc at Deutsche Bank BioFEST - Webcast
Nov 20, 2014
Infinity Pharmaceuticals Inc at Goldman Sachs US Emerging / SMID Cap Growth Conference
Nov 19, 2014
Infinity Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 11, 2014
Infinity Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 6, 2014
Q3 2014 Infinity Pharmaceuticals Inc Earnings Call - Webcast
Nov 6, 2014
Q3 2014 Infinity Pharmaceuticals Inc Earnings Release
Nov 6, 2014
Infinity Pharmaceuticals Inc at Nomura Biotechnology Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 64.25% -
Operating margin 67.05% -
EBITD margin - -
Return on average assets 147.22% -44.77%
Return on average equity 211.28% -49.57%
Employees 151 -
CDP Score - -

Address

780 Memorial Drive
CAMBRIDGE, MA 02139
United States - Map
+1-617-4531000 (Phone)
+1-617-4531001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Infinity Pharmaceuticals, Inc. (IPI) is a drug discovery and development company. The Company's lead product is a potent, oral inhibitor of Class I PI3K-delta and PI3K-gamma, which the Company is investigating in both hematologic malignancies and inflammatory diseases.Its retaspimycin hydrochloride (HCl), is a potent and selective inhibitor of heat shock protein 90 (Hsp90). The phosphoinositide-3-kinases (PI3Ks) are key cellular signaling proteins that act as a central node for relaying signals from cell surface receptors to downstream biochemical events. The Company�s lead development candidate in this program is IPI-145 a potent, oral inhibitor of Class I PI3K-delta,gamma for which clinical trials are conducted form both hematologic malignancies and inflammatory diseases. Hematologic malignancies are cancers of the blood or bone marrow and include leukemia and lymphoma, such as chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma (NHL).

Officers and directors

Adelene Q. Perkins Chairman of the Board, President, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Lawrence E. Bloch M.D., J.D. Chief Financial Officer, Executive Vice President, Chief Business Officer
Age: 49
Bio & Compensation  - Reuters
Julian Adams Ph.D. President - Research & Development
Age: 59
Bio & Compensation  - Reuters
Vito J. Palombella Ph.D. Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
David A. Roth M.D. Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Norman C. Selby Lead Outside Independent Director
Age: 62
Bio & Compensation  - Reuters
Jose Baselga M.D., Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
Jeffrey Berkowitz J.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Gwendolyn A. Fyfe M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters